Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 3Sarcoma 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Her-2 Negative Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Cancer Metastatic 1Advanced Solid Tumors 1

Interventions

Injections 16pembrolizumab 6Bevacizumab 6Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4fludarabine 3Pemetrexed 3Oxaliplatin 3Capecitabine 3toripalimab 2sotorasib 2Immune Checkpoint Inhibitors 2Fulvestrant 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2zimberelimab 1trifluridine tipiracil drug combination 1trametinib 1tislelizumab 1sacituzumab govitecan 1palbociclib 1osimertinib 1olaparib 1lazertinib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumors × fluzoparib × Clear all
NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Risen (Suzhou) Pharma Tech Co., Ltd.

Phase 1/2 Recruiting
306 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡